Content about Prezista

June 29, 2012

Drug maker Gilead Sciences has submitted a regulatory approval application to the Food and Drug Administration for a drug designed to increase the blood levels of certain drugs for HIV.

FOSTER CITY, Calif. — Drug maker Gilead Sciences has submitted a regulatory approval application to the Food and Drug Administration for a drug designed to increase the blood levels of certain drugs for HIV.

June 28, 2011

A subsidiary of Johnson & Johnson and Gilead Sciences will collaborate to develop a combination drug for HIV, the two companies said Tuesday.

CORK, Ireland — A subsidiary of Johnson & Johnson and Gilead Sciences will collaborate to develop a combination drug for HIV, the two companies said Tuesday.

Gilead and Tibotec Pharmaceuticals will work to create a once-daily, single-tablet combination of Tibotec’s Prezista (darunavir) and Gilead’s investigational drug cobicistat, a so-called boosting agent.

May 12, 2011

A subsidiary of Johnson & Johnson is recalling several batches of an HIV drug after reports of a strange odor that may have come from the shipping pallets.

HIGH WYCOMBE, United Kingdom — A subsidiary of Johnson & Johnson is recalling several batches of an HIV drug after reports of a strange odor that may have come from the shipping pallets.

Janssen-Cilag International said it would recall five lots of Prezista (darunavir) due to consumer reports of a musty or moldy smell coming from them. The odor is believed to result from traces of the chemical TBA, which is used in the construction of the pallets. The recalled lots were found in Canada, the United Kingdom, Ireland, Germany and Austria.

November 18, 2010

Johnson & Johnson and the U.S. government are suing two generic drug makers to stop...

NEW YORK — Johnson & Johnson and the U.S. government are suing two generic drug makers to stop them from launching a generic drug for HIV, according to published reports.

 

Bloomberg reported Thursday that Tibotec, a subsidiary of J&J, and the government were separately suing Mylan and Lupin over a generic version of the drug Prezista (darunavir ethanolate), alleging patent infringement.